Synektik (STU:A2P) ROCE %: 70.64% (As of Mar. 2026)

What is Synektik ROCE %?

Synektik STU:A2P +0.89% 85 ROCE % is 70.64% as of Mar. 2026. GuruFocus rates STU:A2P with a GF Score™ of 85/100 and a GF Value™ of €51.60 (Significantly Overvalued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Synektik's annualized ROCE % for the quarter that ended in Mar. 2026 was 70.64%.

Synektik (STU:A2P) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Synektik ROCE % Related Terms

Synektik ROCE % Historical Data

* Premium members only.

The historical data trend for Synektik's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Synektik ROCE % Chart

Synektik Annual Data

Trend

Dec14

Dec15

Dec16

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

ROCE %

Get a 7-Day Free Trial

11.94

10.21

11.64

43.14

59.33

Synektik Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															37.41	63.50	75.81	73.25	70.64

85GF Score

Synektik SA STU:A2P

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Synektik ROCE % Calculation

Synektik's annualized ROCE % for the fiscal year that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Sep. 2024 )		(A: Sep. 2023 )		(A: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Sep. 2024 )		(A: Sep. 2023 )		(A: Sep. 2024 )
	=	29.184	/	( ( (69.865 - 27.542)	+	(87.416 - 31.367) )	/ 2 )
	=	29.184	/	( (42.323	+	56.049)	/ 2 )
	=	29.184	/	49.186
	=	59.33 %

Synektik's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	45.156	/	( ( (141.019 - 66.414)	+	(113.734 - 60.49) )	/ 2 )
	=	45.156	/	( ( 74.605	+	53.244 )	/ 2 )
	=	45.156	/	63.9245
	=	70.64 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 70.64% mean?

Synektik (STU:A2P) has a ROCE % of 70.64% as of Mar. 2026.

Is Synektik's ROCE % too high?

Synektik's current ROCE % is 70.64%. The Medical Devices & Instruments industry median ROCE % is 2.23. Synektik's value of 70.64% is 3067.7% above this industry median. Overall, Synektik has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Synektik's ROCE % compare to ABT and SYK?

Synektik's ROCE % of 70.64% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Synektik's value of 70.64% is 3067.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synektik's current ROCE % of 70.64% is 3067.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synektik's current ROCE % is 70.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Synektik stock overvalued right now?

Based on GuruFocus' analysis, Synektik (STU:A2P) is currently considered Significantly Overvalued. The stock's GF Value™ is €51.60, compared to a current price of €73.85 — trading 43.1% above its estimated fair value. The current ROCE % is 70.64% and 3067.7% above the Medical Devices & Instruments industry median of 2.23. Synektik's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Synektik (STU:A2P), the current ROCE % is 70.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Synektik (STU:A2P) Overvalued in 2026?

Based on GuruFocus' analysis, Synektik stock appears to be overvalued. The current stock price of €73.85 is trading 43.1% above its estimated GF Value™ of €51.60. GuruFocus considers Synektik to be Significantly Overvalued.

Key valuation signals for STU:A2P:

ROCE %: 70.64%
GF Value™: €51.60 vs. price of €73.85 (43.1% above fair value)
GF Score™: 85/100 with 7 warning signs
Industry Position: 3067.7% above the Medical Devices & Instruments median

No single metric tells the full story. See the STU:A2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Synektik Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies WAR:ICE WAR:MDG WAR:GMT WAR:AME WAR:MTN WAR:NST WAR:SDS WAR:GMZ WAR:INM WAR:MSM ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Other Exchanges SNT:Poland A2P:Germany

Address Aleja Wincentego Witosa 31, Warsaw, POL, 00-710

Website http://www.synektik.pl

Synektik SA is a supplier of innovative products, services and IT solutions for diagnostic imaging and nuclear medicine. It sells medical devices and IT solutions used in radiology and operates research laboratory for diagnostic imaging systems and a service centre for medical equipment. Its operating segments include the sale of medical equipment used in radiology and nuclear medicine and IT solutions, Maintenance services for medical equipment as well as acceptance and specialist tests and Radiopharmaceutical production.

85GF Score

Get the complete analysis for STU:A2P

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€73.85

Price

€51.60

GF Value

View STU:A2P Analysis

See ROCE % data for all stocks →